Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19768970 | 0.80 | GABRA1 (0.40) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL21883586 | 0.80 | TSHR (0.38) | CYP1A2CYP3A4TSHRALDH1A1L3MBTL1 | |
| SCHEMBL84270 | 0.77 | TSHR (0.36) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL26596713 | 0.75 | ALDH1A1 (0.35) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL20621249 | 0.75 | TSHR (0.43) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL19779659 | 0.72 | TSHR (0.39) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL21883598 | 0.72 | MAPK1 (0.31) | — | |
| SCHEMBL2423501 | 0.71 | TSHR (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL7645209 | 0.69 | ALDH1A1 (0.37) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL5801541 | 0.68 | ALDH1A1 (0.33) | TSHRALDH1A1L3MBTL1MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | CYP1A2 4769/4885CYP3A4 4648/4885CYP2C9 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.